Linker Information
General Information of This Linker
| Linker ID |
LIN0OHIOM
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
AU2023279443A1, Example A16, Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C52H81N12O21P
|
|||||
| Isosmiles |
CC(C)[C@H](NC([C@@H](NC(CN(C)CCNC(CCOCCOCCOCCOCCNC([C@@H](N1C(C=CC1=O)=O)CNC(CCP(O)(O)=O)=O)=O)=O)=O)CC(N[C@H]2CCOC2=O)=O)=O)C(N[C@H](C(NC3=CC=C(CO)C=C3)=O)CCCNC(N)=O)=O
|
|||||
| InChI |
InChI=1S/C52H81N12O21P/c1-33(2)46(50(75)61-36(5-4-15-56-52(53)77)47(72)58-35-8-6-34(32-65)7-9-35)62-48(73)38(29-42(68)59-37-12-20-85-51(37)76)60-43(69)31-63(3)18-16-54-40(66)13-19-81-22-24-83-26-27-84-25-23-82-21-17-55-49(74)39(64-44(70)10-11-45(64)71)30-57-41(67)14-28-86(78,79)80/h6-11,33,36-39,46,65H,4-5,12-32H2,1-3H3,(H,54,66)(H,55,74)(H,57,67)(H,58,72)(H,59,68)(H,60,69)(H,61,75)(H,62,73)(H3,53,56,77)(H2,78,79,80)/t36-,37-,38-,39-,46-/m0/s1
|
|||||
| InChIKey |
JIHVFESELYPJMW-BQEFHHQISA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1241.257
|
Polar area
|
469.52
|
||
|
Complexity
|
2397.397478
|
xlogp Value
|
-4.9036
|
|||
|
Heavy Count
|
86
|
Rot Bonds
|
43
|
|||
|
Hbond acc
|
20
|
Hbond Donor
|
13
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
AU2023279443A1 Example A16 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | > 50% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
A mixed solvent of PBS and and Matrigel was used to prepare a cell suspension of 5.0x107 cells / mL. The prepared cell suspension was subcutaneously injected to the right flank region of female BALB/c-nu/nu mice at 0.1 mL per mouse. Individuals having a tumor volume within a range of 50 to 500 mm 3 were selected. test compound at a concentration of 3 mg/kg or the solvent alone was intravenously administered. the tumor volume was measured at Day 0 and Day 21.
Click to Show/Hide
|
||||
| In Vivo Model | NCI-N87 female BALB/c-nu/nu mice model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Cell growth inhibition rate (%) | > 14% | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cell growth inhibition test was carried out on HER2-positive human gastric cancer cell line (NCI-N87), the cells were treated with a test compound or an anti-HER2 antibody (trastuzumab) at a concentration of 100 ng/mL. The cells were cultured for 6 days, then CellTiter-Glo was added and the luminescence amount was measured.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||